Breaking News

Tweet TWEET

Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month

Zogenix Launches Improved Migraine Toolbox in Conjunction With National
Migraine Awareness Month

Supports Patient Education and Empowerment for Managing Multiple Types of
Migraine Attacks

SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National
Migraine Awareness Month and in recognition of the significant unmet needs of
migraine sufferers, Zogenix, Inc. (Nasdaq:ZGNX) is launching a new and
improved SUMAVEL^® DosePro^® Migraine Toolbox to support patient education and
empowerment. The Migraine Toolbox highlights the importance of having the
appropriate medication on hand in the patient's "treatment toolbox" to address
the specific migraine attack the patient is experiencing.

Dr. Stephen Silberstein, Professor and Director of the Jefferson Headache
Center at Thomas Jefferson University, Philadelphia, Pennsylvania, said, "The
frequency, intensity and speed of onset of migraines can vary greatly for
patients so it is vital that migraine sufferers follow U.S. Headache
Consortium Migraine treatment guidelines which recommend having access to a
toolbox of treatment options. This includes medication such as oral and
injectable triptan therapies that are fast-acting, convenient and easy-to use
for more aggressive migraine attacks. In addition, education regarding
treatment options is a key component of every migraine patient's treatment
plan."

The Migraine Toolbox reinforces the role of SUMAVEL® DosePro® Needle-free
Delivery System (sumatriptan injection) in treating specific types of migraine
attacks such as those that cause patients to wake up or throw up, or require a
fast-acting backup plan when migraines come on suddenly or recur. A National
Headache Foundation survey of 500 migraine sufferers found that the majority
of sufferers (54 percent) said their prescription oral migraine medication is
not useful for every migraine attack, yet less than 20 percent of such
sufferers use backup prescribed medication when an oral tablet is not an
option.^1

Roger L. Hawley, chief executive officer of Zogenix, said, "Migraine is more
than a headache. The Migraine Toolbox has become a standard part of migraine
care in physician offices across the country where they are using the national
migraine treatment guidelines to enhance outcomes. The patient focus is on
attack-based care which empowers the patient to select the appropriate form of
triptan treatment based on the severity, symptoms and circumstances of that
specific attack. While oral triptans can often be the right choice, many
patients have specific attacks where they know their oral medication may not
give the pain-free outcome they need to be functional. The Toolbox has become
an excellent education resource for migraine suffers and for these physicians
who follow the treatment guidelines. Our goal is to keep making the Migraine
Toolbox better based on customer feedback."

The updated Migraine Toolbox, which is provided to patients by their
physician, is more compact for easy storage and patient use. It contains
several enhancements and important patient education materials, including:

  *Upgraded carrying case for patient migraine treatments
  *One sample dose of SUMAVEL DosePro
  *Migraine journal for tracking migraine attacks and effectiveness of
    treatments
  *Patient education materials, including SUMAVEL DosePro product brochure,
    key card to access an online video demonstrating the use of SUMAVEL
    DosePro, and a reminder card outlining how to use the product
  *Pharmacy convenience materials, including co-pay information and $15
    product card to simplify pharmacy experience

In a survey of more than 1,500 people using SUMAVEL DosePro, 3 out of 4
patients would recommend other migraine sufferers talk to their doctor about
SUMAVEL DosePro.^2 Migraine pain relief can start within 10 minutes with
SUMAVEL DosePro (16 percent of patients vs. 4 percent for placebo), with
studies demonstrating that 82% of patients achieved pain relief at 2 hours
(vs. 35 percent with placebo) and 64 percent of patients were pain free within
2 hours (vs. 15 percent with placebo)^3.

In controlled clinical trials with sumatriptan injection, the most common
adverse reactions were injection site reactions, tingling, warm/hot sensation,
burning sensation, feeling of heaviness, pressure sensation, feeling of
tightness, numbness, feeling strange, tight feeling in head, flushing,
tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort,
dizziness/vertigo, drowsiness/ sedation and headache.

INDICATION and IMPORTANT LIMITATIONS

SUMAVEL DosePro (sumatriptan injection) is indicated for the acute treatment
of migraine attacks, with or without aura, and the acute treatment of cluster
headache episodes.

SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or
for use in the management of hemiplegic or basilar migraine and should not be
administered intravenously. SUMAVEL DosePro should only be used where a clear
diagnosis of migraine or cluster headache has been established. For a given
attack, if a patient does not respond to the first dose of SUMAVEL DosePro,
the diagnosis of migraine or cluster headache should be reconsidered before
administration of a second dose.

IMPORTANT SAFETY INFORMATION

SUMAVEL DosePro is contraindicated in patients with uncontrolled hypertension,
in patients with history, symptoms or signs of ischemic heart disease,
coronary artery vasospasm, cerebrovascular or peripheral vascular disease
including ischemic bowel disease and in patients with other significant
underlying cardiovascular diseases or known hypersensitivity to sumatriptan.
SUMAVEL DosePro should not be given to patients in whom unrecognized coronary
artery disease is predicted by the presence of risk factors without a prior
cardiovascular evaluation.

Serious cardiovascular events, including death, have been reported when taking
sumatriptan, including patients with no findings of cardiovascular disease.
Considering the extent of use of sumatriptan in patients with migraine, the
incidence of these events is extremely low. Cerebrovascular events, some
fatal, have been reported in patients treated with sumatriptan. In a number of
cases, it appears possible that the cerebrovascular events were primary,
sumatriptan having been administered in the incorrect belief the symptoms
experienced were a consequence of migraine when they were not. It is important
to advise patients not to administer SUMAVEL DosePro if a headache being
experienced is atypical.

Do not use SUMAVEL DosePro and any ergotamine-containing or ergot-type
medication within 24 hours of each other; do not use SUMAVEL DosePro and
another 5-HT1 agonist (e.g. triptan) within 24 hours of each other (with the
exception of a single dose of another sumatriptan product, provided the doses
are separated by at least 1 hour). SUMAVEL DosePro is not generally
recommended for use with MAO-A inhibitors. The development of a potentially
life-threatening serotonin syndrome may occur with triptans, including
treatment with SUMAVEL DosePro, particularly during combined use with
selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine
reuptake inhibitors (SNRIs). SUMAVEL DosePro should be used during pregnancy
only if the potential benefit justifies the potential risk.

In controlled clinical trials with sumatriptan injection, the most common
adverse reactions were injection site reactions, tingling, warm/hot sensation,
burning sensation, feeling of heaviness, pressure sensation, feeling of
tightness, numbness, feeling strange, tight feeling in head, flushing,
tightness in chest, discomfort in nasal cavity/sinuses, jaw discomfort,
dizziness/vertigo, drowsiness/sedation and headache.

For full prescribing information, go to
http://www.zogenix.com/downloads/SV0468.0611_SDP_PI.pdf

For more information about SUMAVEL DosePro, please visit
http://www.sumaveldosepro.com/.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain.
Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection)
Needle-free Delivery System, was launched in January 2010 for the acute
treatment of migraine and cluster headache. Zogenix's lead investigational
product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral,
extended-release formulation of various strengths of hydrocodone, without
acetaminophen, intended for administration every 12 hours for around the clock
management of moderate to severe chronic pain. In May 2012, Zogenix submitted
to the FDA a New Drug Application for Zohydro ER. Zogenix's second
investigational product candidate, Relday™, is a proprietary, long-acting
injectable formulation of risperidone for the treatment of schizophrenia; an
investigational new drug application was submitted to the FDA in May 2012.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"intends," "potential," "suggests," "assuming" and similar expressions are
intended to identify forward-looking statements. These statements are based on
the company's current beliefs and expectations. These forward-looking
statements include statements regarding SUMAVEL DosePro's usefulness as a
therapeutic option in relieving migraine pain and symptoms. The inclusion of
forward-looking statements should not be regarded as a representation by
Zogenix that any of its plans will be achieved. Actual results may differ from
those set forth in this release due to the risk and uncertainties inherent in
Zogenix's business, including, without limitation: unexpected adverse side
effects relating to Sumavel DosePro that could result in recalls or product
liability claims; and other risks described in the company's prior press
releases and filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Zogenix undertakes no
obligation to revise or update this release to reflect events or circumstances
after the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under the safe
harbor provisions of Section 21E of the Private Securities Litigation Reform
Act of 1995.

SUMAVEL^®, DosePro^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,
Inc.

                                     FPR

^1
http://www.headaches.org/press/NHF_Press_Releases/2010-Press_Releases/2010_NHAW_Press_Release

^2 http://www.sumaveldosepro.com/what-people-are-saying

^3 http://www.sumaveldosepro.com/efficacy


CONTACT: Investors
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
        
         Media
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.